180 related articles for article (PubMed ID: 32343928)
1. DDP-resistant ovarian cancer cells-derived exosomal microRNA-30a-5p reduces the resistance of ovarian cancer cells to DDP.
Liu R; Zhang Y; Sun P; Wang C
Open Biol; 2020 Apr; 10(4):190173. PubMed ID: 32343928
[TBL] [Abstract][Full Text] [Related]
2. Exosomal miR-21-5p derived from cisplatin-resistant SKOV3 ovarian cancer cells promotes glycolysis and inhibits chemosensitivity of its progenitor SKOV3 cells by targeting PDHA1.
Zhuang L; Zhang B; Liu X; Lin L; Wang L; Hong Z; Chen J
Cell Biol Int; 2021 Oct; 45(10):2140-2149. PubMed ID: 34288231
[TBL] [Abstract][Full Text] [Related]
3. Exosome-Derived Circ-PVT1 Contributes to Cisplatin Resistance by Regulating Autophagy, Invasion, and Apoptosis Via miR-30a-5p/YAP1 Axis in Gastric Cancer Cells.
Yao W; Guo P; Mu Q; Wang Y
Cancer Biother Radiopharm; 2021 May; 36(4):347-359. PubMed ID: 32799541
[No Abstract] [Full Text] [Related]
4. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.
Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H
Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364
[TBL] [Abstract][Full Text] [Related]
5. Circ_0007841 knockdown confers cisplatin sensitivity to ovarian cancer cells by down-regulation of NFIB expression in a miR-532-5p-dependent manner.
Gao Y; Huang Y
J Chemother; 2023 Apr; 35(2):117-130. PubMed ID: 35380509
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
Qin X; Yu S; Zhou L; Shi M; Hu Y; Xu X; Shen B; Liu S; Yan D; Feng J
Int J Nanomedicine; 2017; 12():3721-3733. PubMed ID: 28553110
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of circ-PIP5K1A overcomes resistance to cisplatin in ovarian cancer by miR-942-5p/NFIB axis.
Sheng H; Wang X
Anticancer Drugs; 2023 Feb; 34(2):214-226. PubMed ID: 36730637
[TBL] [Abstract][Full Text] [Related]
8. MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells.
Zuo Y; Zheng W; Liu J; Tang Q; Wang SS; Yang XS
Neoplasma; 2020 Jan; 67(1):93-101. PubMed ID: 31777260
[TBL] [Abstract][Full Text] [Related]
9. Linc00852 from cisplatin-resistant gastric cancer cell-derived exosomes regulates COMMD7 to promote cisplatin resistance of recipient cells through microRNA-514a-5p.
Cao S; Fu B; Cai J; Zhang D; Wang C; Wu H
Cell Biol Toxicol; 2023 Apr; 39(2):483-496. PubMed ID: 35088190
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of long non-coding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated EZH2 and SIRT1.
Zhang Y; Ai H; Fan X; Chen S; Wang Y; Liu L
Biol Res; 2020 Apr; 53(1):18. PubMed ID: 32349783
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-132 reverses cisplatin resistance and metastasis in ovarian cancer by the targeted regulation on Bmi-1.
Zhang XL; Sun BL; Tian SX; Li L; Zhao YC; Shi PP
Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3635-3644. PubMed ID: 31114988
[TBL] [Abstract][Full Text] [Related]
12. MiR-30a-5p Enhances Cisplatin Sensitivity by Downregulating RIF1 in Ovarian Cancer.
Yao W; Wang Y; Huang M; Zhou J; Zheng R; Jin C; Zhang Y
Ann Clin Lab Sci; 2023 May; 53(3):418-426. PubMed ID: 37437929
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA miR-30a inhibits cisplatin resistance in ovarian cancer cells through autophagy.
Cai Y; An B; Yao D; Zhou H; Zhu J
Bioengineered; 2021 Dec; 12(2):10713-10722. PubMed ID: 34747309
[TBL] [Abstract][Full Text] [Related]
14. Exosome-transmitted circVMP1 facilitates the progression and cisplatin resistance of non-small cell lung cancer by targeting miR-524-5p-METTL3/SOX2 axis.
Xie H; Yao J; Wang Y; Ni B
Drug Deliv; 2022 Dec; 29(1):1257-1271. PubMed ID: 35467477
[TBL] [Abstract][Full Text] [Related]
15. Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer.
Chen Y; Cao XY; Li YN; Qiu YY; Li YN; Li W; Wang H
Am J Physiol Cell Physiol; 2018 Aug; 315(2):C225-C235. PubMed ID: 29719173
[TBL] [Abstract][Full Text] [Related]
16. Toosendanin reduces cisplatin resistance in ovarian cancer through modulating the miR-195/ERK/β-catenin pathway.
Wang G; Li L; Li Y; Zhang LH
Phytomedicine; 2023 Jan; 109():154571. PubMed ID: 36610147
[TBL] [Abstract][Full Text] [Related]
17. Silencing of miR-1246 Induces Cell Cycle Arrest and Apoptosis in Cisplatin-Resistant Ovarian Cancer Cells by Promoting ZNF23 Transcription.
Cai L; Zhang Q; Du L; Zheng F
Cytogenet Genome Res; 2021; 161(10-11):488-500. PubMed ID: 34923485
[TBL] [Abstract][Full Text] [Related]
18. Linc00161 regulated the drug resistance of ovarian cancer by sponging microRNA-128 and modulating MAPK1.
Xu M; Zhou K; Wu Y; Wang L; Lu S
Mol Carcinog; 2019 Apr; 58(4):577-587. PubMed ID: 30556928
[TBL] [Abstract][Full Text] [Related]
19. MiR-30a-5p/CHD1 axis enhances cisplatin sensitivity of ovarian cancer cells via inactivating the Wnt/β-catenin pathway.
Wang X; Zhao H; Wang P; Zhang J; Li N; Liu Y; Zhang F; Yu Y
Anticancer Drugs; 2022 Nov; 33(10):989-998. PubMed ID: 36206129
[TBL] [Abstract][Full Text] [Related]
20. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway.
Hu Z; Cai M; Zhang Y; Tao L; Guo R
Cell Cycle; 2020 Jan; 19(2):193-206. PubMed ID: 31885310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
